Does a high arachidonic acid to EPA ratio indicate a pro-inflammatory omega-6-dominant pattern?

The balance between omega-6 and omega-3 polyunsaturated fatty acids in cell membranes serves as a critical biological dial, regulating both the initiation and resolution of the inflammatory response.

Biomarker dynamics and pro-inflammatory signaling

• A high arachidonic acid (AA) to eicosapentaenoic acid (EPA) ratio acts as a direct biomarker of an omega-6-dominant pattern, creating a strong substrate bias in cell membranes.
• Under inflammatory stimuli, AA and EPA compete for the same cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. An elevated AA:EPA ratio ensures preferential conversion of AA into highly active, pro-inflammatory lipid mediators, specifically 2-series prostaglandins (such as $\text{PGE}_2$) and 4-series leukotrienes (such as $\text{LTB}_4$).
• Increasing EPA levels competitively displaces AA from these enzymatic pathways, shifting synthesis toward weaker 3-series prostaglandins and 5-series leukotrienes, thereby dampening systemic inflammatory tone.

Substrate-limited resolution pathways

• EPA is the obligatory, primary precursor required for the synthesis of E-series specialized pro-resolving mediators (SPMs), including resolvins $\text{RvE1}$, $\text{RvE2}$, $\text{RvE3}$, and $\text{RvE4}$, which actively coordinate the termination of inflammation.
• The rate-limiting step in resolvin synthesis involves the enzymatic conversion of EPA into 18-hydroxy-eicosapentaenoic acid (18-HEPE) via COX-2 or cytochrome P450 pathways.
• Depleted cellular EPA directly restricts the availability of the 18-HEPE gateway substrate. This substrate deficiency severely limits downstream 5-lipoxygenase-dependent conversion, making the synthesis of complex, highly active SPMs like $\text{RvE1}$ virtually undetectable.

Bottom line

• Key takeaway: A high AA:EPA ratio drives a systemic bias toward the production of potent pro-inflammatory lipid mediators ($\text{PGE}_2$, $\text{LTB}_4$) while simultaneously depleting 18-HEPE, the obligatory substrate required to synthesize E-series resolvins necessary to resolve inflammation.